130 related articles for article (PubMed ID: 29807678)
41. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
42. Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?
Hendriks LE; Bootsma GP; de Ruysscher DK; Scheppers NA; Hofman PA; Brans BT; Dingemans AM
Lung Cancer; 2013 Jun; 80(3):293-7. PubMed ID: 23518381
[TBL] [Abstract][Full Text] [Related]
43. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
[TBL] [Abstract][Full Text] [Related]
44. Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy.
MacManus MP; Hicks RJ; Ball DL; Ciavarella F; Binns D; Hogg A; Kalff V; Ware R; Wirth A; Salminen E; McKenzie A
Australas Radiol; 2001 Nov; 45(4):483-90. PubMed ID: 11903182
[TBL] [Abstract][Full Text] [Related]
45. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
46. Fluorodeoxyglucose positron emission tomography for detection of tumor recurrence following radiofrequency ablation in retrospective cohort of stage I lung cancer.
Wang Y; Lanuti M; Bernheim A; Shepard JO; Sharma A
Int J Hyperthermia; 2018; 35(1):1-8. PubMed ID: 29719997
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic imaging in dermatology: utility of PET-CT in cutaneous melanoma.
Sánchez-Sánchez R; Serrano-Falcón C; Rebollo Aguirre AC
Actas Dermosifiliogr; 2015; 106(1):29-34. PubMed ID: 24661948
[TBL] [Abstract][Full Text] [Related]
48. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
Kahn D; Menda Y; Kernstine K; Bushnell D; McLaughlin K; Miller S; Berbaum K
Chest; 2004 Feb; 125(2):494-501. PubMed ID: 14769730
[TBL] [Abstract][Full Text] [Related]
49. [Findings of the (18)F-FDG PET-CT in a cardiac angiosarcoma complicated by a cardiac rupture].
Santiago-Chinchilla A; Ruiz-Carazo E; Moral-Ruiz A; Testart Dardel N; Martínez-Martínez A; López-Fernández S
Rev Esp Med Nucl Imagen Mol; 2014; 33(4):227-30. PubMed ID: 23810660
[TBL] [Abstract][Full Text] [Related]
50. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer.
Bury T; Paulus P; Dowlati A; Corhay JL; Weber T; Ghaye B; Schoffers J; Limet R; Albert A; Rigo P; Radermecker M
Eur Respir J; 1996 Dec; 9(12):2560-4. PubMed ID: 8980969
[TBL] [Abstract][Full Text] [Related]
51. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
[TBL] [Abstract][Full Text] [Related]
52. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
53. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
Bury T; Corhay JL; Duysinx B; Daenen F; Ghaye B; Barthelemy N; Rigo P; Bartsch P
Eur Respir J; 1999 Dec; 14(6):1376-80. PubMed ID: 10624770
[TBL] [Abstract][Full Text] [Related]
54. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F
Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616
[TBL] [Abstract][Full Text] [Related]
55. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
56. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
57. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
58. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
59. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
[TBL] [Abstract][Full Text] [Related]
60. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?
Ayan AK; Erdemci B; Orsal E; Bayraktutan Z; Akpinar E; Topcu A; Turkeli M; Seven B
Rev Esp Med Nucl Imagen Mol; 2016; 35(2):102-6. PubMed ID: 26521996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
